Program Start: 7:30 AM - 9:30 AM Registration Begins 30 minutes prior.
As corporate directors undergo transformational changes within their industries and organizations, it is imperative that they are vigilant about the many exciting innovations helping lead this period of disruption and change. These innovations can be found in the form of products and services, many of which are developed and practiced in the incubation hub that is New England. These products and services are disrupting and transcending all industries and are occurring in life sciences, manufacturing, financial services, agriculture, and education, to name a few.
The pace of innovation is fast, and will only continue to build steam. New discoveries are being uncovered, monetized and placed into service daily, from new and improved health care devices to the use of edge computing and the Internet of Things to enhance security or improve supply chain efficiency. These are just a few examples of the transformational technologies that board members must grasp and put into perspective in order to place their organizations ahead of the disruptive and transformational curve.
On October 8, 2019, NACD New England will showcase four New England-based companies whose products and services are changing the world. The leaders of these organizations will share their company's mission and vision, while virtually opening the doors to their labs and thought leadership centers. Inquiring minds are encouraged to take part in an expanded Q&A session, moderated by Corey Thomas, CEO, Rapid7.
Disruption and change are imperative—are you prepared?
Alison Lawton, CEO, Kaleido BioSciences
Alison Lawton has served as Kaleido’s Chief Executive Officer, President and as a member of the Board of Directors since August 2018, after initially joining the company as President and Chief Operating Officer in December 2017. Ms. Lawton has more than 30 years of experience in a range of executive and operating roles in the biopharmaceutical industry. Prior to joining Kaleido, she was COO at Aura Biosciences, and previously held the same role at X4 Pharmaceuticals and OvaScience. Ms. Lawton spent more than 20 years at Genzyme Corporation and subsequently at Sanofi, following its acquisition of Genzyme. She served as Senior Vice President and General Manager of Sanofi Biosurgery, a $750 million business that included surgical, orthopedics and cell therapy and regenerative medicine franchises. Earlier, as SVP of Global Market Access for Genzyme, Ms. Lawton led global functional organizations, including regulatory affairs and quality systems, public policy, health outcomes and strategic pricing, product safety and risk management. Additionally, Ms. Lawton worked for seven years in the U.K. at Warner-Lambert/Parke-Davis. She previously served two terms as the industry representative on the Food & Drug Administration’s Cell & Gene Therapy Advisory Committee and as Chairman of the Board of the Regulatory Affairs Professional Society (RAPS). She is currently an independent Director of ProQR Therapeutics and Verastem, Inc., and was previously a director on the boards of Cubist Pharmaceuticals, CoLucid Pharmaceuticals and Magenta Therapeutics. Ms. Lawton earned her Bachelor of Science degree in Pharmacology from King’s College London.
Debbie Millin, COO, Globalization Partners
Debbie Millin has more than 20 years of operational, project management, and client relationship experience across a variety of industries. She specializes in helping companies experiencing rapid growth scale their systems and processes.
Debbie helped grow Globalization Partners to be the No. 1 fastest growing women-led company in America, and has helped two different companies achieve the honor of No. 1 fastest-growing private company in Massachusetts — including Globalization Partners in 2017.
She serves on the Board of Directors and Executive Committee for Special Olympics of Massachusetts, as well as the Corporate Advisory Board for The Commonwealth Institute, and is a long-standing member of The Boston Club.
David Perry, CEO Indigo AG
David Perry, President, CEO, and Director, Indigo. He is a serial entrepreneur who has founded and built three innovative companies in the last 20 years, leading the last two through successful IPOs and to multi-billion dollar market capitalizations and raising over $1.2 billion while generating significant returns for investors.
David was most recently CEO and Co-Founder of Anacor Pharmaceuticals (NASDAQ: ANAC), a biopharmaceutical company discovering and developing novel small-molecule therapeutics to treat infectious and inflammatory diseases. The company was acquired by Pfizer Inc. (NYSE: PFE) in 2016 for approximately $5.2 billion. David previously cofounded and served as CEO of Chemdex (NASDAQ: CMDX), later creating its parent company Ventro Corporation (NASDAQ: VNTR), a business-to-business marketplace focused on the life sciences industry. At its peak, Ventro was valued at $11 billion and was later sold to Nexprise.
David is Founder and Chairman of the San Francisco-based digital health startup Better Therapeutics (f/k/a FareWell) and a Board Director of the human microbiome company Evelo Biosciences.
In 2000, David was named Entrepreneur of the Year in Northern California by Ernst and Young. He holds an M.B.A. from Harvard Business School and a B.S. in chemical engineering from the University of Tulsa. He also attended the United States Air Force Academy, where he was a National Merit Scholar.
Andy Ory, Co-Founder of 128 Technologies
Andy Ory, co-founder, 128 Technology, has served as the company’s Chief Executive Officer and board member since inception. Prior to 128 Technology, Andy co-founded Acme Packet in August 2000 and served as its Chief Executive Officer and President until Acme Packet’s acquisition in 2013. Andy also founded Priority Call Management and served as its Chief Executive Officer and Chairman. Andy holds a B.A. from Harvard University. Moderator:
Corey Thomas, CEO, Rapid7
In addition to being president and CEO, Corey is also a member of the Rapid7 board of directors. In 2018 he was elected to the Cyber Threat Alliance (CTA) board of directors, and he also serves on the Blue Cross Blue Shield of Massachusetts board of directors, and sits on its audit and health care quality and affordability committees. Corey has extensive experience leading technology companies to the next stage of growth and innovation. His previous positions include VP of marketing at Parallels, Inc., a virtualization technology company; group project manager of the Microsoft Server and Tools division, launching the worldwide availability of SQL Server 2005 and steering product planning for Microsoft’s data platform; and a consultant at Deloitte Consulting. Corey received a B.E. in electrical engineering and computer science from Vanderbilt University and a MBA from Harvard Business School.